No association of low‐dose aspirin with severe COVID‐19 in France: A cohort of 31.1 million people without cardiovascular disease
-
Published:2022-04
Issue:4
Volume:6
Page:e12743
-
ISSN:2475-0379
-
Container-title:Research and Practice in Thrombosis and Haemostasis
-
language:en
-
Short-container-title:Research and Practice in Thrombosis and Haemostasis
Author:
Botton JérémieORCID,
Semenzato LauraORCID,
Dupouy JulieORCID,
Dray‐Spira RosemaryORCID,
Weill AlainORCID,
Saint‐Lary OlivierORCID,
Zureik MahmoudORCID
Reference17 articles.
1. Should aspirin be used for prophylaxis of COVID‐19‐induced coagulopathy?;Mohamed‐Hussein;Med Hypotheses,2020
2. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in‐hospital mortality in hospitalized patients with coronavirus disease 2019;Chow;Anesth Analg,2021
3. Clinical impact of pre‐admission antithrombotic therapy in hospitalized patients with COVID‐19: a multicenter observational study;Russo;Pharmacol Res,2020
4. Aspirin use for primary cardiovascular prevention during the covid‐19 pandemic;Siegel;Am J Med,2021
5. Aspirin in patients admitted to hospital with COVID‐19 (RECOVERY): a randomised, controlled, open‐label, platform trial;Abani;Lancet,2022
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献